Drug Trial Radar · NCT07326878
Phase I Clinical Trial of Enterovirus Type71 - Coxsackievirus Type A16 Bivalent Vaccine
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
Dec 30, 2025
Primary completion
Aug 15, 2026
Study completion Aug 15, 2027
Sponsor
- Lead sponsor
- Institute of Medical Biology, Chinese Academy of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Second Affiliated Hospital of Chongqing Medical University
- First posted
- Jan 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 59 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of the Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine in subjects ( aged 6 months to 59 years ).
Conditions
- Hand, Foot and Mouth Disease (HFMD)
- HFMD
- Hand, Foot and Mouth Disease
Interventions
Low Dose Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine, inactivated (human diploid cell)Biological
Low-dose vaccine,dosage and immunization procedure: 0.1 ml/dose, 2 doses, 28-day interval
Medium Dose Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine, inactivated (human diploid cell)Biological
Medium-dose vaccine,dosage and immunization procedure: 0.1 ml/dose, 2 doses, 28-day interval
High Dose Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine, inactivated (human diploid cell)Biological
High-dose vaccine,dosage and immunization procedure: 0.1 ml/dose, 2 doses, 28-day interval
PlaceboBiological
Placebo,dosage and immunization procedure: 0.1 ml/dose, 2 doses, 28-day interval
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety index - incidence of adverse eventsTime frame: 0- 30 minutes/Day 0 to 7 days/Day 0 to 28 days after each dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.